Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leiomyoma 4Papillomavirus Infections 3Inflammation 2Frailty 2Uterine Cervical Dysplasia 1Triple Negative Breast Neoplasms 1Squamous Intraepithelial Lesions 1Radiodermatitis 1Prostatic Neoplasms 1Papilloma 1Liver Neoplasms 1Liver Cirrhosis 1Fibrosis 1Esophageal Neoplasms 1Deglutition Disorders 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Atypical Squamous Cells of the Cervix 1

Interventions

Radiotherapy 2Exercise 2Deglutition 2Cisplatin 2Carboplatin 2Brachytherapy 2Acupuncture Therapy 2tislelizumab 1epigallocatechin gallate 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Tablets 1Standard of Care 1Resistance Training 1Range of Motion, Articular 1Radiotherapy, Intensity-Modulated 1Radiation 1Pravastatin 1Paclitaxel 1Niacinamide 1Musculoskeletal Manipulations 1Lead 1Hyaluronic Acid 1Gastropexy 1Fundoplication 1Fluorouracil 1Fibroblast Growth Factor 7 1Esophagectomy 1Endoscopy, Digestive System 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Deglutition Disorders × epigallocatechin gallate × Clear all
NCT06398405 2024-05-03

A Phase II Clinical Study of Epigallocatechin-3-gallate in Patients With Esophageal Squamous Cancer

Shandong Cancer Hospital and Institute

Phase 2 Unknown
72 enrolled
Gastrointestinal

Deglutition Disorders, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡